{"transactions":[{"id":1047289,"issuer":{"id":694,"kind":"organization","name":"Perspective Therapeutics, Inc.","symbol":"CATX"},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-09-05T20:06:51.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on September 4, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date."}],"balance_after":600000,"derivative":{"exercise_price":3.54,"expiration_date":"2035-09-04","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000950170-25-113245","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/728387/000095017025113245/ownership.xml","form_type":"4"}},{"id":3713460,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy","published_at":"2019-01-03T00:16:35.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":65000,"derivative":{"exercise_price":6.26,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000899243-19-000178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924319000178/doc4.xml","form_type":"4"}},{"id":3871858,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-07T01:44:42.000Z","date":"2018-07-05","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vested as to 25% on May 1, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":165833,"derivative":{"exercise_price":5.9,"expiration_date":"2027-07-05","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000899243-18-019567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/doc4.xml","form_type":"4"}},{"id":3871857,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-07-07T01:44:42.000Z","date":"2018-07-05","kind":"sale","acquired":false,"shares":2000,"price":17.5,"value":35000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 10,181 shares of common stock held by the Joel D. Sendek Retained Annuity Trust No. 1, of which the Reporting Person is a trustee."}],"balance_after":15181,"source":{"system":"sec-edgar","filing":"0000899243-18-019567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/doc4.xml","form_type":"4"}},{"id":3871856,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-07-07T01:44:42.000Z","date":"2018-07-05","kind":"exercise","acquired":true,"shares":2000,"price":5.9,"value":11800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 10,181 shares of common stock held by the Joel D. Sendek Retained Annuity Trust No. 1, of which the Reporting Person is a trustee."}],"balance_after":17181,"source":{"system":"sec-edgar","filing":"0000899243-18-019567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/doc4.xml","form_type":"4"}},{"id":4130422,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-15T21:06:51.000Z","date":"2017-12-13","kind":"grant","acquired":true,"shares":27795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":27795,"derivative":{"exercise_price":11.63,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":27795},"source":{"system":"sec-edgar","filing":"0000899243-17-028850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317028850/doc4.xml","form_type":"4"}},{"id":4170252,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series C Preferred Stock","published_at":"2017-11-07T21:05:32.000Z","date":"2017-11-06","kind":"exercise","acquired":false,"shares":61880,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Joel D.  Sendek Retained Annuity Trust No. 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10181},"source":{"system":"sec-edgar","filing":"0000899243-17-025507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025507/doc4.xml","form_type":"4"}},{"id":4170251,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-11-07T21:05:32.000Z","date":"2017-11-06","kind":"purchase","acquired":true,"shares":5000,"price":14,"value":70000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering."}],"balance_after":15181,"source":{"system":"sec-edgar","filing":"0000899243-17-025507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025507/doc4.xml","form_type":"4"}},{"id":4170250,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":75774,"kind":"person","name":"Sendek Joel","position":1,"cik":"0001720875","reported_name":"Sendek Joel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-11-07T21:05:32.000Z","date":"2017-11-06","kind":"exercise","acquired":true,"shares":10181,"ownership":{"direct":false,"nature":"Joel D. Sendek Retained Annuity Trust No. 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."}],"balance_after":10181,"source":{"system":"sec-edgar","filing":"0000899243-17-025507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025507/doc4.xml","form_type":"4"}}]}